Table 5.
Adjusted changes in metabolic variables in patients with overweight and obese that received either vitamin D supplement or placebo.
| Placebo group1 (n = 29) | Vitamin D group2 (n = 30) | P ∗ | |
|---|---|---|---|
| Serum 25(OH)D (ng/mL) | 0.2 ± 0.87 | 15 ± 0.6 | <0.001 |
| Omentin-1 (ng/L) | 12.4 ± 0.11 | 16.5 ± 0.11 | 0.1 |
| Spexin (pg/mL) | 122.3 ± 0.15 | 184 ± 0.14 | 0.3 |
| hs-CRP (ng/mL) | −95.13 ± 754.3 | −783.96 ± 832.12 | 0.01 |
| sICAM-1(ng/L) | −209.3 ± 77.6 | −316.8 ± 76.3 | 0.01 |
| FBS (mg/dL) | 103.2 ± 2.8 | 97.8 ± 2.8 | 0.1 |
| Triglycerides (mg/dL) | 5.7 ± 11.9 | 38.9 ± 11 | 0.01 |
| HDL-cholesterol (mg/dL) | 0.52 ± 1.6 | 8.3 ± 1.6 | 0.01 |
| LDL-cholesterol (mg/dL) | 4.9 ± 0.4 | −8.4 ± 0.4 | 0.1 |
| Total cholesterol (mg/dL) | −7.4 ± 16.8 | −18.5 ± 0.5 | 0.1 |
| VLDL-C (mg/dL) | 2.1 ± 41.2 | 15.3 ± 0.9 | 0.01 |
FBS: fasting blood sugar; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; and VLDL-C: very-low-density lipoprotein-cholesterol. 1Received placebo per day during 8 weeks. 2Received 2,000 IU vitamin D per day during 8 weeks. ∗Significant difference (P < 0.05). ∗Obtained from ANCOVA test adjusted for baseline values, age, and baseline BMI. Data are presented as means ± SDs.